To determine the results of allogeneic hematopoietic stem cell (HSC) transplantation for chronic myelogenous leukemia (CML) at various stages of the disease in children, a retrospective analysis was carried out on the outcome of transplants performed on 76 children and teenagers with CML between 1982 and 1998. In all, 60 patients were transplanted from a matched sibling donor (MSD) and 16 from a matched unrelated donor (MUD). There was a higher incidence of acute graft-versus-host disease after MUD transplantation (Po10 À3 ). The main cause of death was transplant-related toxicity in both groups. In MSD recipients, the probability of relapse at 5 years for patients transplanted in the first chronic phase was lower than in patients transplanted in the advanced phase (relative risk (rr) ¼ 5.90; 95% confidence interval (CI), 1.85-18.82, Po0.01). The estimated 5-year eventfree survival (EFS) rate was higher after MSD vs MUD transplantation (61% (95% CI, 48-73%) vs 27% (95% CI, 4-49%), rr ¼ 0.25, Po10
Summary:
To determine the results of allogeneic hematopoietic stem cell (HSC) transplantation for chronic myelogenous leukemia (CML) at various stages of the disease in children, a retrospective analysis was carried out on the outcome of transplants performed on 76 children and teenagers with CML between 1982 and 1998. In all, 60 patients were transplanted from a matched sibling donor (MSD) and 16 from a matched unrelated donor (MUD). There was a higher incidence of acute graft-versus-host disease after MUD transplantation (Po10 À3 ). The main cause of death was transplant-related toxicity in both groups. In MSD recipients, the probability of relapse at 5 years for patients transplanted in the first chronic phase was lower than in patients transplanted in the advanced phase (relative risk (rr) ¼ 5.90; 95% confidence interval (CI), 1.85-18.82, Po0.01). The estimated 5-year eventfree survival (EFS) rate was higher after MSD vs MUD transplantation (61% (95% CI, 48-73%) vs 27% (95% CI, 4-49%), rr ¼ 0.25, Po10
À3
). In children transplanted from MSD, the 5-year EFS was higher when transplantation was performed in the first chronic phase vs the advanced phases (73% (95% CI, 59-87%) vs 32% (95% CI, 10-54%), Po10 À3 ). Disease status at transplantation was the unique factor influencing survival in patients undergoing transplantation from MSD with a better outcome for those transplanted in the first chronic phase. Allogeneic HSC offers a possibility of curing childhood CML with a significant advantage for patients transplanted in chronic phase using a human leukocyte antigenidentical sibling donor. Bone Marrow Transplantation (2003) 32, 993-999. doi:10.1038/sj.bmt.1704255
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Despite therapeutic advances with the use of interferon (IFN)-based regimens 1, 2 and the promising perspectives of targeted therapy with a specific tyrosine kinase inhibitor, 3, 4 allogeneic bone marrow transplantation (BMT) remains the only reported curative strategy in younger patients with Philadelphia chromosome-positive chronic myelogenous leukemia (CML). 5 However, data concerning the role of allogeneic BMT in the treatment of children and teenagers with CML have been obtained on cohorts of a limited number of patients and the impact of factors affecting transplant outcome are not well defined. [6] [7] [8] This report from the Socie´te´Franc¸aise de Greffe de Moelle et de The´rapie Cellulaire (SFGM-TC) reviews 76 patients under 18 years of age suffering from CML who were given an allogeneic hematopoietic stem cell (HSC) transplant from a human leukocyte antigen (HLA)-matched sibling donor (MSD) or a matched unrelated donor (MUD) . We analyze the impact of patient, disease and treatment factors with transplant outcome.
Patients and methods

Data collection
This analysis is based on data reported to the SFGM-TC registry of bone marrow transplants performed between January 1982 and October 1998. Information concerning the donor, recipient, harvesting procedure and follow-up was collected by transplant centers using prospectively designed forms. Data included details of patient and donor age, sex, histocompatibility, dates of diagnosis and transplant, stage of disease and outcome. Stage of disease (chronic phase, accelerated phase or blastic crisis) was classified according to the criteria of the International Bone Marrow Transplant Registry (IBMTR) 9 and relapse was defined by investigators as hematological, cytogenetic or molecular relapse. a Second or (higher) chronic phase, accelerated phase or blast crisis. Abbreviations: Cy, cyclophosphamide; Ara-C, cytosine arabinoside; Mel, melphalan; Bu, busulfan; CsA, cyclosporine; mab, monoclonal antibodies; ATG, antithymocyte globulin.
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The median follow-up duration for survivors after relateddonor HSC transplantation was 112 months (range, 21-217) and 40 months for unrelated-donor bone marrow recipients (range, 2-54). Two patients were lost to followup (5 and 10 years after BMT, respectively).
Preparative regimen and graft-versus-host disease (GVHD) prophylaxis
Pretransplant conditioning regimens were divided into two categories according to the use of total body irradiation (TBI). In all, 53 (70%) patients were given chemotherapy and TBI, whereas 23 (30%) patients were conditioned using chemotherapy alone. Details concerning TBI were not available in five patients. In 16 patients TBI was given as a single dose, while the other 32 children received fractionated TBI. The median dose of TBI was 12 Gy (range, 9-15).
Most of the patients (69%) conditioned with fractioned TBI received a total dose of 12 Gy in six fractions. GVHD prophylaxis consisted of cyclosporine (CsA) alone or in combination with steroids in 18 (24%) patients, methotrexate (MTX) alone in four (5%) patients, CsA and MTX in 54 (71%) patients (10 of whom also received steroids or monoclonal antibodies or antithymocyte globulin) and ex vivo T-cell depletion in four patients. The median number of donor-nucleated cells infused (available in 56 patients) was 2.85 Â 10 
Assessment of engraftment, GVHD and relapse
Engraftment was defined as recovery of granulocytes to 0.5 Â 10 9 /l for 3 consecutive days. Trilineage engraftment was documented by bone marrow examination in the majority of patients 3-4 weeks after transplantation. Chimerism was evaluated by karyotype analysis on bone marrow cells and blood lymphocytes, red blood cell antigen phenotyping or studying genetic polymorphism of a variable number of tandem repeated short DNA sequences. Late graft failure was defined as the occurrence of sustained neutropenia in patients who had previously engrafted. Acute and chronic GVHD were diagnosed and graded according to standard criteria. 10, 11 Patients who had evidence of engraftment were evaluable for acute GVHD. The probability of chronic GVHD was evaluated in patients who survived for at least 100 days with sustained engraftment. Transplant-related mortality was defined as death resulting from any causes other than relapse. Disease recurrence was defined by the detection of any type of relapse (molecular, cytogenetic or hematologic) and the need of antileukemic therapy.
Definitions of end points
Survival, leukemia-free survival, transplant-related mortality, acute and chronic GVHD and relapse were calculated from BMT. As the monitoring strategy to detect disease relapse differed from one center to another, leukemia-free survival was defined as survival without hematologic, cytogenetic or molecular evidence of relapse in blood or bone marrow. Transplant-related mortality was defined as death due to causes other than disease recurrence.
Data reporting for analysis was updated as of January 1, 2001 .
Statistical analysis
Comparisons between groups were performed with the use of Fisher's exact test for categorical variables and Wilcoxon's two-sample test for continuous variables. Survival and time to events were calculated from the date of transplant. Overall survival, disease-free survival and event-free survival (EFS) distributions were estimated by the Kaplan-Meier method and compared using the logrank test. The relative risk of deaths, relapses or events was calculated using the Cox model. Survival was also estimated according to the Gratwohl risk scoring system. 12 Cox's regression and the log-rank test were used to explore the influence of prognostic factors (donor and recipient gender and cytomegalovirus serology, disease stage at transplantation, interval from diagnosis to transplantation, transplantation performed before or after 1990, TBIcontaining preparative regimen, occurrence of acute or chronic GVHD) on survival or events in univariate analyses. The small size of the patient cohort did not allow multivariate analyses. All statistical tests of significance were two tailed and analyses were performed using the SAS statistical software (SAS Institute, Cary, NC, USA).
Results
Engraftment
Of the 76 patients, three graft failures were observed after MUD transplantation (one patient failed to engraft and an additional two had late graft failure). The median time to achieve an absolute neutrophil count greater than 0.5 Â 10 9 / l was 25 days (range, 12-60) in 63 patients. In 37 patients, chimerism studies were uninformative but these patients had sustained hematopoietic recovery. Chimerism was documented in 37 patients with engraftment: full chimerism occurred in 33 patients, mixed chimerism in two patients and autologous reconstitution occurred in two patients.
Graft-versus-host-disease
In total, 75 patients were evaluable for acute GVHD (Table 2) . Acute GVHD was more frequent in patients transplanted from MUD (Po0.01). Grade II-IV acute GVHD occurred in 28% of patients transplanted from HLA-identical siblings and in 80% of patients given BMT from an unrelated donor (Po0.001). Severe acute GVHD, defined as grades III and IV, occurred in 40% of patients who received unrelated bone marrow and in 15% of the recipients of sibling bone marrow (Po0.05). Chronic GVHD affected 25 (38%) of 65 children who survived more than 100 days after BMT. It was limited in nine cases and extensive in 16 cases (Table 2 ). A significant difference was observed in the incidence of chronic GVHD between patients transplanted using MSD and MUD (33 vs 75%, respectively, P ¼ 0.05).
Allogeneic transplantation in childhood CML F Millot et al
Causes of death
In all, 31 MSD patients died -19 (32%) and 12 (75%) MUD patients. Causes of death are summarized in Table 3 . The main cause of death was transplant-related complications. A total of 23 patients died from transplant-related complications between 2 months and 7 years (median, 4 months) after transplantation. Among them, 10 (43%) transplant-related deaths occurred before day 100 after transplantation (three were observed in the MSD group and seven in the MUD group). Death was associated with treatment-resistant GVHD in nine patients (four patients in the MSD group and five in the MUD group). Infections contributed to six deaths. The percentage of deaths due to transplant-related causes was 92% for patients transplanted using an unrelated donor and 63% in children given BMT from a sibling donor HLA identical. Six patients died from recurrent CML between 3 months and 14 years (median, 21 months) after transplantation.
Relapses
In all, 15 patients (14 MSD recipients and one MUD recipient) experienced a relapse: hematologic, cytogenetic and molecular relapses occurred, respectively, in 11, three and one patients resulting in a probability of relapse of 23% (95% confidence interval (CI), 12-35%) at 5 years. The median time for the occurrence of relapse for the entire group was 24 months (range, 1-78 months). In children transplanted from an MSD, the probability of relapse at 5 years was lower when transplantation was performed in the first chronic phase than in the advanced phase (15% (95% CI, 3-27) vs 52% (95% CI, 24-79%), respectively, rr ¼ 5.90, Po0.01). The median time of relapse for the first chronic phase MSD recipients and advanced phases MSD recipients was 44 months (range, 24-78 months) and 7 months (range, 2-29 months), respectively.
Survival
The overall survival of the 76 patients was 64% (95% CI, 53-75%) at 5 years ( Figure 1 ). The overall survival for children transplanted from an MSD was 73% (95% CI, 62-84%), whereas the survival rate for patients given BMT from an MUD was 27% (95% CI, 4-49%) at 5 years (rr ¼ 0.19, 95% CI, 0.09-0.41, Po10 À4 ). At the time of analysis, 58% of the 76 patients were alive -67% of those transplanted from an MSD and 25% of those transplanted from an MUD. The 5-year Kaplan-Meier EFS rate of the entire group was 54% (95% CI, 42-65%). The EFS at 5 years for children transplanted from an MSD was 61% (95% CI, 48-73%), whereas the EFS for patients given BMT from an MUD was 27% (95% CI, 4-49%) (Figure 2) . At 5 years, the EFS in the first chronic phase MSD recipients was 73% (95% CI, 59-87%), while the EFS in the advanced phase MSD recipients was 32% (95% CI, 10-54%) Po0.01 (rr ¼ 0.25, Po0.01) (Figure 3 ). Survival at 5 years was 82% (95% CI, 64-100%), 74% (95% CI, 57-91%), 67% (95% CI, 45-89%) and 50% (95% CI, 0-100%) for patients with score 0, 1, 2 and 4, respectively, according to the Gratwohl scoring system; all patients with score 3 died at 1 year and no patients belonged to score 5. Univariate analysis of factors related to patients, CML and transplant influencing survival was performed in patients transplanted from an MSD. Within Table 2 Patients' clinical outcome Months from transplant Probability of survival Figure 1 Probability of survival of the 76 patients.
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F Millot et al the limitation of the small number of patients in this cohort, disease status at transplantation was the only factor affecting survival, with a better outcome for patients transplanted in the first chronic phase (Po0.02).
Discussion CML is a rare disease in children, accounting for 2-5% of childhood leukemia cases. 13 Series including exclusively pediatric patients transplanted for CML are very rare and concern cohorts of a limited number of patients. [6] [7] [8] The present study of a large cohort of children and teenagers with CML indicates that HSC transplantation results in long-term survival in more than half of the patients with an MSD. The median survival of our patients transplanted in the first chronic phase from a geno-identical sibling has not yet been reached more than 10 years after BMT. Mortality from causes other than CML relapse in this subset of patients is relatively high with more than half of the patients dying of nonrelapse causes. This finding could be explained, in part, by the fact that our study included patients transplanted in the 1980s. Recent studies have reported low transplant-related mortality rates among patients transplanted from a matched sibling, who receive modern regimens for prevention of GVHD and opportunistic infections.
14 In the present study, early transplantation within the first year of diagnosis was offered to most of the children with an HLA-compatible sibling donor, but this did not influence the outcome. Our patients transplanted in the first chronic phase with related marrow grafts had a significantly lower incidence of relapse and a better outcome than did patients transplanted with an advanced phase of CML, indicating that disease status at transplantation influences ultimate survival. Similar findings are reported in adults. 5 The 5-year EFS rate (73%) of our patients transplanted in the first chronic phase compares favorably with results of large cohorts of young adults transplanted from matched related donors. [15] [16] [17] The influence of age on outcome is reported in various studies in which younger patients (under 30 years of age) have longer disease-free survivals and lower transplant-related mortalities than do older patients. 18 In the present study, univariate analysis failed to reveal any significant factors influencing survival (except disease status at transplantation) partly because of the small size of the group analyzed. The rates of relapse in our patients who underwent HSC transplantation from HLA-identical siblings are within the expected range of 15-25% reported in adults. Late relapses among related-donor recipients transplanted in an advanced phase of CML were not recorded, while relapse more than 5 years later occurred in a first chronic phase recipient. Our study emphasizes that children and adolescents continue to be at risk for relapse for many years following related-donor transplantation in the first chronic phase of CML. A similar finding was reported in a series of 373 adults who continued to relapse at a rate of 1.5% per year more than 2 years after BMT for CML in the chronic phase. 19 Post transplant relapses, including late relapses, remain a problem in patients with a matched-sibling donor. 20 However, uncontrolled studies reported a longterm survival advantage for HLA-identical sibling transplants over hydroxyurea or IFN-alpha in CML. 5, 17, 21 In our study, results obtained using unrelated matched donors have been discouraging, with a high transplantrelated mortality rate due in part to severe acute GVHD and refractory chronic GVHD. Treatment-related mortality is higher after transplantation from an unrelated donor, 22 but tends to be lower because preparative regimens, stem cells sources, prophylactic regimens against GVHD and methods of supportive care have changed in recent years. 23 Molecular typing of DRB1 alleles allows more accurate donor/recipient matching and improves clinical outcome after unrelated marrow transplantation. 24 In our study, early and late graft failures were observed in children receiving bone marrow from an unrelated donor. The incidence of graft failure is reported to be higher in patients receiving unrelated stem cell. 23, 25, 26 A more advanced stage of the disease at transplantation has contributed unfavorably to patient outcome in our patients transplanted from an unrelated donor. Disease stage at transplantation is an important factor that affects survival after unrelated BMT. 20, 27 McGlave et al 28 reported a 5-year survival rate of 64% in a series of 157 unrelated-donor bone marrow transplants in patients under 35 years of age transplanted in the early chronic phase. In addition, Allogeneic transplantation in childhood CML F Millot et al a minority of our patients transplanted from an unrelated donor received transplantation within the first year of diagnosis. A prolonged interval (more than 12 months) between diagnosis and transplant has been reported to increase the transplant-related mortality rate in unrelateddonor recipients as well as in related-donor recipients. 19, 12, 20, 27 Performing the transplant procedure as soon as possible could improve results.
Our retrospective analysis of data from different transplant centers has inherent limitations. The study period was long (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) and criteria for transplantation and conditioning protocols differed throughout the study and among centers. The monitoring strategy to detect relapse differed from one center to another, implying that leukemia-free survival was defined as survival without hematologic, cytogenetic or molecular evidence of relapse in the blood or bone marrow. Moreover, complete information concerning pretransplant therapy was not available, reducing the possibility of studying subsets of patients.
The optimal strategy in children with CML remains difficult to define. The usefulness of the prognostic scores used for adults with CML has not been established in children. Very little data are available concerning the use of IFN alone or in combination with chemotherapy in this age group. We previously reported that the combination of IFN and cytosine arabinoside induces complete hematologic and major cytogenetic responses and is well tolerated in children without HLA-identical donors. 29 However, longterm follow-up data demonstrated persistence of a complete cytogenetic response in only a minority of adults with CML receiving IFN-based therapy. Stem cell transplantation is required in children without complete hematologic remission or major cytogenetic response, 3 and 12 months, respectively, after the start of IFN-based therapy. Scant data concerning the use of imatinib mesylate are available in children and prospective trials are needed to define the efficiency and tolerance of tyrosine kinase inhibitors in this age group. Allogeneic HSC transplantation is a potentially curative therapy in children, but long-term toxicity must be considered.
This work includes the largest group of children and teenagers with CML given an allogeneic BMT reported to date. Our data support the conclusion that allogeneic BMT offers the possibility of curing most patients transplanted in the chronic phase using an HLA-identical sibling donor. The role of promising agents such as imatinib mesylate needs to be evaluated in children and adolescents with CML in order to make the optimal therapeutic choice.
